不久前，华福证券发布医药生物行业研报称：全球虽仅一款TSLP单抗上市，但2024年销售额有望突破10亿美元，胸腺基质淋巴细胞生成素即TSLP是IL-2类多效能细胞因子，在免疫反应尤其是二型免疫反应中发挥重要作用，参与过敏性疾病、慢性炎症性疾病等过程。

本次2025 ...

ORLANDO -- More than 80% of patients with moderate or severe atopic dermatitis (AD) had at least 75% improvement after 12 ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

Binding and crosslinking experiments demonstrate that this protein is the receptor for a recently described interleukin 7 (IL-7)-like factor, thymic stromal lymphopoietin (TSLP). Binding of TSLP ...

**NM signifies a non meaningful value. A dash signifies the data is not available.

为探究嗜酸性粒细胞（EOS）和混合 / 中性粒细胞（MIXED）哮喘表型差异，研究人员评估相关指标，发现重度或频发加重的 MIXED 哮喘患者血管增多、TSLP 和血管生成素过表达，提示其与血管重塑有关。 在哮喘的世界里，它就像一个难以捉摸的 “小怪兽”，以慢性气 ...

Chronic rhinosinusitis with nasal polyps presents a substantial clinical burden, affecting nasal airflow, olfactory function, ...

过去康方生物的双抗平台已经通过AK-104和AK-112完成了在肿瘤领域的验证，AK-139作为公司首个进入临床的自免双抗，以及作为一个全球First in class的自免双抗分子，其后续数据进展备受投资者期待。

Real time quote data is not available at this time.